MacroGenics Dividends and Buybacks
Dividend criteria checks 0/6
MacroGenics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-0.5%
Buyback Yield
| Total Shareholder Yield | -0.5% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
MacroGenics: A Productive Biotech With Growing Potential - Still Not A Buy
Dec 05Party Time: Brokers Just Made Major Increases To Their MacroGenics, Inc. (NASDAQ:MGNX) Earnings Forecasts
Aug 01
MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Jul 30We're A Little Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Jul 12MacroGenics, Inc.'s (NASDAQ:MGNX) 81% Dip In Price Shows Sentiment Is Matching Revenues
May 13MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)
May 13MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024
Apr 05MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Feb 28MacroGenics: Trying To Build A Better Everything
Feb 15There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues
Jan 09Benign Growth For MacroGenics, Inc. (NASDAQ:MGNX) Underpins Its Share Price
May 17Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher
Mar 11Here's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash Wisely
Jan 25Analysts' Revenue Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher
Oct 25MacroGenics: No Near-Term Catalysts
Oct 11Israel Englander and his Millennium fund disclose 5.2% passive stake in MacroGenics
Sep 02MacroGenics Q2 2022 Earnings Preview
Aug 05Companies Like MacroGenics (NASDAQ:MGNX) Could Be Quite Risky
Jul 25MacroGenics halts mid-stage head and neck cancer study after fatalities
Jul 11The Consensus EPS Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Just Fell Dramatically
May 09We're Keeping An Eye On MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Apr 12Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if MGNX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MGNX's dividend payments have been increasing.
Dividend Yield vs Market
| MacroGenics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (MGNX) | n/a |
| Market Bottom 25% (US) | 1.5% |
| Market Top 25% (US) | 4.5% |
| Industry Average (Biotechs) | 2.5% |
| Analyst forecast (MGNX) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate MGNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MGNX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate MGNX's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MGNX has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 17:50 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
MacroGenics, Inc. is covered by 25 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Etzer Darout | BMO Capital Markets Equity Research |
| Stephen V. Byrne | BofA Global Research |